Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zabinostat - IngenOx Therapeutics

Drug Profile

Zabinostat - IngenOx Therapeutics

Alternative Names: AZD 9468; CXD101; Zabadinostat

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Cancer Research UK; IngenOx Therapeutics; Merck Sharp & Dohme; National Institute for Health Research; Nuance Biotech; Oxford University Hospitals NHS Trust; Syneos Health; University College London
  • Class Anti-inflammatories; Antihyperlipidaemics; Antineoplastics; Cardiovascular therapies; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Hodgkin's disease; Liver cancer; Peripheral T-cell lymphoma
  • Phase I/II Diffuse large B cell lymphoma
  • No development reported Lymphoma

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for phase-I development in Lymphoma(Second-line therapy or greater) in China (PO, Capsule)
  • 24 May 2023 IngenOx Therapeutics in collaboration with Chinese University of Hong Kong plans a phase II trial for Liver cancer (Second line therapy or greater, Combination therapy) in Hong Kong (PO) in September 2023 (NCT05873244)
  • 13 Feb 2023 Ingenox Therapeutics initiates a phase II HACCA trial in Liver cancer (PO) (Ingenox Therapeutics pipeline, February 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top